Compounds > spirodecanone
Page last updated: 2024-11-06

spirodecanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Spirodecanone is a cyclic ketone with a spiro ring system. It has been synthesized via various methods, including ring-closing metathesis and Diels-Alder reactions. Spirodecanone derivatives have shown interesting biological activities, such as anti-inflammatory and anti-cancer properties. The unique structural features of spirodecanone make it a valuable building block for the synthesis of complex molecules and pharmaceuticals. Spirodecanone has been studied as a potential template for drug development due to its ability to interact with specific biological targets.'

Cross-References

ID SourceID
PubMed CID70556
CHEMBL ID309711
SCHEMBL ID219618
MeSH IDM0063647

Synonyms (51)

Synonym
AC-6487
CHEMBL309711 ,
1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one
bdbm50044436
4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane
1,3,8-triazaspiro[4.5]decan-4-one,1-phenyl-
spirodecanone
1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
1,3,8-triazaspiro[4.5]decan-4-one, 1-phenyl-
1021-25-6
nsc-96918
nsc96918
smr000036952
MLS000080523
1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one, >=96.0% (hplc)
1-phenyl-1,3,8-triazaspiro-[4,5]decan-4-one
AKOS005067461
A1791
1-phenyl-1,3,8-triazaspiro(4,5)decan-4-one
einecs 213-819-5
nsc 96918
STK574453
HMS2443P11
1-phenyl-4-oxo-1,3,8-triazaspiro[4,5]decane
1-phenyl-1,3,8-triaza-spiro[
1-phenyl-1,3,8-triaza-spiro[4,5]decan-4-one
1-phenyl-1,3,8-triazaspiro[
FT-0630036
AB00551
SCHEMBL219618
1-phenyl-1,3,8-triazaspiro-[4.5]decan-4-one
4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]decane
1-phenyl-1,3,8-triazaspiro[4.5]-decan-4-one
1-phenyl-1,3,8-triazaspiro[4,5]-decan-4-one
1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one
1-phenyl-1,3,8-triazaspiro[4.5]decane-4-one
1-phenyl-1,3,8-triazaspiro [4,5]decan-4-one
1-phenyl -1,3,8-triaza-spiro[4.5]decan-4-one
4-oxo-1-phenyl-1,3,8-triazaspiro-[4.5]decane
W-204446
mfcd00005977
DTXSID00144635
spirodecanone;1,3,8-triazaspiro[4.5]decan-4-one, 1-phenyl-
BCP20803
CS-0067287
AS-39092
CCG-275144
4-oxo-1-phenyl-1,3-diaza-8-azoniaspiro[4.5]decane
1-phenyl-4-oxo-1,3,8-triazaspiro[4.5]decane
EN300-15316
SY011190

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.04470.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency0.31620.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency0.31620.025120.237639.8107AID886
thioredoxin reductaseRattus norvegicus (Norway rat)Potency63.09570.100020.879379.4328AID588453
PINK1Homo sapiens (human)Potency28.18382.818418.895944.6684AID624263
ParkinHomo sapiens (human)Potency28.18380.819914.830644.6684AID624263
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki10.00000.00020.667710.0000AID4766; AID5295
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki10.00000.00010.601710.0000AID5295
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki10.00000.00010.739610.0000AID4338
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki10.00000.00020.590910.0000AID5295
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID4338Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist.
AID4766Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist.
AID5295Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (30.77)18.7374
1990's3 (23.08)18.2507
2000's1 (7.69)29.6817
2010's4 (30.77)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.67 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pentobarbital
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		6.9810barbituratesGABAA receptor agonist
spiperone
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.		2.8840aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
lenperone
lenperone: antipsychotic of the butyrophenone class; like other major tranquilizers, it has some alpha-adrenergic blocking action & is antiemetic; minor descriptor (76-85); on-line & Index Medicus search BUTYROPHENONES (76-85); RN given refers to parent cpd		1.9810
spiramide
spiramide: RN given refers to parent cpd; structure. spiramide : An azaspiro compound that consists of 1,3,8-triazaspiro[4.5]decan-4-one having a phenyl group attached to N-1 and a 3-(4-fluorophenoxy)propyl attached to N-8. Selective 5-HT antagonist, which binds to 5-HT2 sites as potently as spiperone but has lower affinity for 5-HT2C receptors. Also a high affinity D2 receptor antagonist (Ki = 3 nM). Lacks the disruptive effect of spiperone on animal behaviour.		1.9810aromatic ether;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
serotonergic antagonist
vinconate
vinconate: synthetic hexa-hydrocanthane alkaloid; RN given refers to (+ -)-isomer; RN for cpd without isomeric designation not avai lable 8/89		6.9810
butaclamol
Butaclamol: A benzocycloheptapyridoisoquinolinol that has been used as an antipsychotic, especially in schizophrenia.		1.9510
neurotensin
neurotensin, Tyr(11)-: RN given refers to parent cpd & (D)-isomer; RN for cpd without isomeric designation not avail 5/91		3.0710peptide hormonehuman metabolite;
mitogen;
neurotransmitter;
vulnerary
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		01.9610
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9610
Anterior Circulation Transient Ischemic Attack
[description not available]		02.3920
Ischemic Attack, Transient
Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)		02.3920